ST Pharm Co.,Ltd.
Price Chart
Key facts
- Market Cap
- ₩1.52T
- P/E
- 26.8x
- P/B
- 2.49x
- ROE
- 10.0%
ST Pharm Co.,Ltd.
No description on file.
- CEO
- Sung Moo-je
- Employees
- 0
- Website
- stpharm.co.kr
No description on file.
| Fiscal year | Revenue | Operating income | Net income | Operating margin |
|---|---|---|---|---|
| 2025 | ₩331.68B | ₩54.93B | ₩54.56B | 16.6% |
| 2024 | ₩273.75B | ₩27.69B | ₩32.46B | 10.1% |
| 2023 | ₩284.99B | ₩33.51B | ₩17.52B | 11.8% |
| 2022 | ₩249.32B | ₩17.85B | ₩17.52B | 7.2% |
Teragen Etex, SK Biopharmaceuticals, ST Pharm, Celltrion Pharmaceutical, Prestige Biopharma, Prestige Biologics, Apogen Biologics, Kolon Life Science, Hanall Biopharma, and Samchundang Pharmaceutical are all on a downward trend. Huons, Vivocell Pharmaceuticals...
pinpointnewsNov 6, 2026
Celltrion Pharmaceutical, Hanall Biopharma, Apogen Biologics, Prestige Biopharma, Prestige Biologics, Samchundang Pharmaceutical, Kolon Life Science, Selbion, Ilyang Pharmaceutical, and ST Pharm are involved in new drug development, biopharmaceutical production, technology exports, and...
pinpointnewsNov 3, 2026
Dong-A ST and ST Pharm log Q3 sales, profit gains in South Korea Q3 results show steady momentum at Dong-A ST and ST Pharm despite forex drag
Biz.ChosunOct 27, 2026
Sources: Financials from DART filings, as filed. Prices and analyst consensus from licensed data providers. Latest annual results: fiscal 2025, period ended . Not investment advice. DART filings · How this data is collected · Report an error
West Pharmaceutical Services Raises Dividend 18%
MarketwatchOct 19, 2026
TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $410 to $420.
BenzingaOct 13, 2026